Rev. Soc. Esp. Dolor. 2023; 30(2): 72-78 / DOI: 10.20986/resed.2023.4028/2022
Benjamín Folgueira, Elena María Brozos, Juan Carlos Cámara, Luis Olay, María Belén González, Oliver Higuera, Patrícia Ramirez, Hugo Arasanz Arasanz, Enrique García
ABSTRACT
Objective: To assess the degree of satisfaction of patients and/or caregivers with transmucosal fentanyl citrate treatment in the management of breakthrough cancer pain crises in terms of ease of use.
Methods: An observational, prospective and multicenter study was carried out with 48 patients undergoing maintenance treatment with opioids for baseline chronic cancer pain and who, in addition, suffered breakthrough pain crises for those who were receiving treatment with fentanyl citrate. The main variable of the study was the degree of satisfaction of the patients and/or their caregivers with fentanyl citrate in the management of breakthrough cancer pain crises, evaluated
by means of Visual Analogue Scale (VAS) questionnaires.
Results: 90.6 % of patients/caregivers show a high degree of satisfaction with the use of fentanyl citrate in terms of ease of use (mean VAS value of 8.2). For its part, both the general assessment by the patients/caregivers and by the healthcare professionals has been very positive (mean VAS value 7.7).
Conclusions: Fentanyl citrate is an easy-to-use and effective therapy for the treatment of breakthrough cancer pain crises, widely accepted by both patients and caregivers as well as health professionals.
RESUMEN
Objetivo: Evaluar el grado de satisfacción de los pacientes y/o cuidadores con el tratamiento de citrato de fentanilo transmucosa en la gestión de las crisis de dolor irruptivo oncológico en términos de facilidad de uso.
Métodos: Se realizó un estudio observacional, prospectivo y multicéntrico con 48 pacientes sometidos a tratamiento de mantenimiento con opioides para el dolor crónico basal provocado por el cáncer y que, además, sufrían crisis de dolor irruptivo para las que estaban recibiendo tratamiento con citrato de fentanilo. La variable principal del estudio fue el grado de satisfacción de los pacientes y/o sus cuidadores con el citrato de fentanilo en el manejo de las crisis de dolor irruptivo oncológico, evaluadas mediante cuestionarios Escala Visual Analógica (EVA).
Resultados: El 90,6 % de los pacientes/cuidadores muestran un elevado grado de satisfacción con el empleo de citrato de fentanilo en términos de facilidad de uso (valor medio EVA de 8,2). Por su parte, tanto la valoración general por parte de los pacientes/cuidadores como por parte de los sanitarios ha sido muy positiva (valor medio EVA 7,7).
Conclusiones: El citrato de fentanilo es una terapia fácil de usar y eficaz para el tratamiento de las crisis de dolor irruptivo oncológico, con amplia aceptación tanto por parte de pacientes y cuidadores como de los profesionales sanitarios.
Nuevo comentario
Comentarios
No comments in this article
Bibliografía
1. Escobar Álvarez Y, Rodríguez Sánchez CA, Caballero Martínez F, Recuero Cuervo V, Camps Herrero C. Professional survey on knowledge and clinical patterns of pain management in Spanish medical oncology. Clin Transl Oncol. 2010;12(12):819-24.
2. Jara C, del Barco S, Grávalos C, Hoyos S, Hernández B, Muñoz M, et al. SEOM clinical guideline for treatment of cancer pain (2017). Clin Transl Oncol. 2018;20(1):97-107.
3. van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-Analysis. J Pain Symptom Manage. 2016;51(6):1070-1090.e9.
4. Mercadante S, Gatti A, Porzio G, Lo Presti C, Aielli F, Adile C, et al. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Curr Med Res Opin. 2012;28(6):963-8.
5. Manirakiza A, Irakoze L, Manirakiza S, Bizimana P. Efficacy and Safety of Fentanyl Compared With Morphine among Adult Patients with Cancer: A Meta-Analysis. East African Heal Res J. 2020;4(1):8-16.
6. Simpson DM, Messina J, Xie F, Hale M. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29(4):588-601.
7. Daeninck P, Gagnon B, Gallagher R, Henderson JD, Shir Y, Zimmermann C, et al. Canadian recommendations for the management of breakthrough cancer pain. Curr Oncol. 2016;23(2):96-108.
8. Cánovas Martínez L, Rodríguez Rodríguez AB, Castro Bande M, Arviza LP, Soto CL, Román Nuñez R. Tratamiento del dolor irruptivo. Rev Soc Esp Dolor. 2012;19(6):318-24.
9. Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain. 2002;3(1):38-44.
10. Husic S, Imamovic S, Matic S, Sukalo A. Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care. Med Arch (Sarajevo, Bosnia Herzegovina). 2017;71(4):246-50.
11. Schug SA, Ting S. Fentanyl Formulations in the Management of Pain: An Update. Drugs. 2017;77(7):747-763.
12. Fallon M, Reale C, Davies A, Lux AE, Kumar K, Stachowiak A, et al. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: A multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. J Support Oncol. 2011;9(6):224-31.
13. Mercadante S, Ferrera P, Adile C, Casuccio A. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: Preliminary data on the proportionality between breakthrough pain dose and background dose. J Pain Symptom Manage. 2011;42(3):464-9.
14. Dietrich E, Gums JG. Intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain. Ann Pharmacother. 2012;46(10):1382-91.
15. Mercadante S. The use of rapid onset opioids for breakthrough cancer pain: The challenge of its dosing. Crit Rev Oncol Hematol. 2011;80(3):460-5.
16. Messina J, Darwish M, Fine PG. Fentanyl buccal tablet. Drugs of Today. 2008;44(1):41-54.
17. Mercadante S, Gatti A, Porzio G, Lo Presti C, Aielli F, Adile C, et al. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Curr Med Res Opin. 2012;28(6):963-8.
18. Ashburn M, Fine P, Stanley T. Oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: A case report. Anesthesiology. 1989;71:615-7.
19. Jandhyala R, Fullarton JR, Bennett MI. Efficacy of Rapid-Onset Oral Fentanyl Formulations vs. Oral Morphine for Cancer-Related Breakthrough Pain: A meta-analysis of comparative trials. J Pain Symptom Manage. 2013;46(4):573-80.
20. Jandhyala R, Fullarton J. Various formulations of oral transmucosal fentanyl for breakthrough cancer pain: An indirect mixed treatment comparison meta-analysis. BMJ Support Palliat Care. 2012;2(2):156-62.
21. Farrar JT, Cleary J, Rauck R, Busch M, Nordbrock E. Oral transmucosal fentanyl citrate: Randomized, double-blinded, placebo- controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst. 1998;90(8):611-6.
22. Burton AW, Driver LC, Mendoza TR, Syed G. Oral transmucosal fentanyl citrate in the outpatient management of severe cancer pain crises: a retrospective case series. Clin J Pain. 2004;20(3):195-7.
23. Zeppetella G, Ribeiro MD. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane database Syst Rev. 2006;(1).